T1D Exchange
101 Federal Street, Suite 440, Boston, MA, 02110, United States
Overview
The goal of T1D Exchange is to bring together the best of traditional clinical and biological research with the expanding fields of health information technology and virtual community-building. By delivering a platform to our partners that facilitates an unprecedented knowledge exchange between the research community, Type 1 diabetics, and their caregivers, the T1D Exchange links the entire Type 1 Diabetes community in its efforts to accelerate research and improve healthcare for all Type 1s. The idea is to replicate this model to other disease states globally. The T1D Exchange began as a three-year project funded by the Leona M. and Harry B. Helmsley Charitable Trust in 2010. The T1D Exchange platform is comprised of three core components: Glu, clinical registry, and Biobank.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Diabetes
- Health Care
Investment portfolio
- Bigfoot Biomedical
Participated · Series B · Mar 2018
Bigfoot Biomedical is a Milpitas, California–based medical device company that develops therapy and telemedicine solutions for people with insulin-requiring Type 1 and Type 2 diabetes. Its lead product under development, the Bigfoot Unity System, is part of the Bigfoot Unity Diabetes Management Program and provides real-time dose-decision support for users on Multiple Daily Injection (MDI) therapy. Unity uses proprietary smart pen caps for basal and mealtime insulin dosing recommendations and integrates Abbott’s FreeStyle Libre glucose-sensing platform. The company plans to package Unity as a monthly subscription that includes pen caps, Abbott sensing technology, needles, a backup glucose meter, test strips, alcohol swabs and a mobile app, while insulin pens are obtained separately. Bigfoot also develops the Bigfoot Autonomy pump-based closed-loop automated insulin delivery system, which has received FDA Breakthrough Device designation and will require a pivotal trial and regulatory approvals. The company is led by CEO Jeffrey Brewer. Bigfoot Biomedical develops AI-driven diabetes solutions aimed at optimizing insulin dosing and delivery for people with insulin-requiring diabetes. Its product programs include Bigfoot Loop, an infusion pump–based closed-loop automated insulin delivery system, and Bigfoot Inject, a connected insulin pen decision‑support system for people on injection therapy. The company has an agreement with Abbott to integrate Abbott's FreeStyle Libre glucose‑sensing technology into Bigfoot's ecosystem. Bigfoot plans to use recent financing to support ongoing product development, clinical trials, and commercialization of its Class III investigational systems. The company reported completing a $55 million Series B and has raised over $90 million in equity to date. Bigfoot is based in Milpitas, California.
Team
No current team members are available.